Trial Profile
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-5737 in Subjects With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Idrevloride (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 17 Jun 2014 New trial record